Cardiac action potential action potential (see phase 2, below) and is a fundamental step in cardiac excitation-contraction coupling. There are important physiological differences between the cells that spontaneously generate the action potential (pacemaker cells; e.g. SAN) and those that simply conduct it (non-pacemaker cells; e.g. ventricular myocytes). The specific differences in the types of ion channels expressed and mechanisms by which they are activated results in differences in the configuration of the action potential waveform, as shown in figure 2. The standard model used to understand the cardiac action potential is that of the ventricular myocyte. Outlined below are the five phases of
Cardiac glycoside heart rate without significant changes in heart rate or blood pressure; this quality allows it to be widely used medicinally in the treatment of cardiac arrhythmias. Cardiac glycosides have long served as the main medical treatment to congestive heart failure and cardiac arrhythmia, due to their effects of increasing the force of muscle contraction while reducing heart rate. Heart failure is characterized by an inability to pump enough blood to support the body, possibly due to a decrease in the volume of the blood or its contractile force. Treatments for the condition thus focus on lowering blood pressure, so that